Skip to main content

Advertisement

SpringerLink
Log in

Leishmaniasis: new insights from an old and neglected disease

  • Review
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Leishmaniases are a clinically heterogeneous group of diseases caused by protozoa of the genus Leishmania. There is growing evidence that the true incidence of the disease is underestimated, especially in hyperendemic regions. Moreover, climate changes together with the increasing movement of humans and animals raise concerns about the possible introduction of Leishmania infection in previously spared areas. The disease is emerging in immunocompromised patients undergoing bone marrow or solid organ transplantation or treatment with biologic drugs. Furthermore, the deployment of military troops and travel to endemic areas are associated with the observation of a growing number of patients with cutaneous disease. Improvement in diagnostic methods, both in the field and in specialized laboratories, has been obtained through the implementation of molecular amplification methods and using the rK39 antigen as the substrate. Finally, new therapeutic approaches are gaining attention, such as the use of miltefosine for cutaneous leishmaniasis and paromomycin for visceral leishmaniasis, as well as the use of various antileishmanial drugs in combination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Al-Mutawakel K, Scutaru C, Shami A, Sakr M, Groneberg DA, Quarcoo D (2010) Scientometric analysis of the world-wide research efforts concerning Leishmaniasis. Parasit Vectors 3:14

    Article  PubMed  Google Scholar 

  2. Pratt DM, David JR (1981) Monoclonal antibodies that distinguish between New World species of Leishmania. Nature 291:581–583

    Article  PubMed  CAS  Google Scholar 

  3. Lainson R, Shaw JJ (1987) Evolution, classification and geographical distribution. In: Peters W, Killick-Kendrick R (eds) The leishmaniases in biology and medicine. Academic Press, London, pp 1–120

    Google Scholar 

  4. Rioux JA, Lanotte G, Serres E, Pratlong F, Bastien P, Perieres J (1990) Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification. Ann Parasitol Hum Comp 65:111–125

    PubMed  CAS  Google Scholar 

  5. Bañuls AL, Hide M, Prugnolle F (2007) Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol 64:1–109

    Article  PubMed  Google Scholar 

  6. Lukes J, Mauricio IL, Schönian G, Dujardin JC, Soteriadou K, Dedet JP, Kuhls K, Tintaya KW, Jirků M, Chocholová E, Haralambous C, Pratlong F, Oborník M, Horák A, Ayala FJ, Miles MA (2007) Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc Natl Acad Sci USA 104:9375–9380

    Article  PubMed  CAS  Google Scholar 

  7. Fraga J, Montalvo AM, De Doncker S, Dujardin JC, Van der Auwera G (2010) Phylogeny of Leishmania species based on the heat-shock protein 70 gene. Infect Genet Evol 10:238–245

    Article  PubMed  CAS  Google Scholar 

  8. Schönian G, Mauricio I, Cupolillo E (2010) Is it time to revise the nomenclature of Leishmania? Trends Parasitol 26:466–469

    Article  PubMed  Google Scholar 

  9. Bern C, Maguire JH, Alvar J (2008) Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2:e313

    Article  PubMed  Google Scholar 

  10. Singh SP, Reddy DC, Rai M, Sundar S (2006) Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health 11:899–905

    Article  PubMed  CAS  Google Scholar 

  11. Singh VP, Ranjan A, Topno RK, Verma RB, Siddique NA, Ravidas VN, Kumar N, Pandey K, Das P (2010) Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India. Am J Trop Med Hyg 82:9–11

    Article  PubMed  Google Scholar 

  12. Das P, Samuels S, Desjeux P, Mittal A, Topno R, Siddiqui NA, Sur D, Pandey A, Sarnoff R (2010) Annual incidence of visceral leishmaniasis in an endemic area of Bihar, India. Trop Med Int Health 15(Suppl 2):4–11

    Article  PubMed  Google Scholar 

  13. Dujardin JC, Campino L, Cañavate C, Dedet JP, Gradoni L, Soteriadou K, Mazeris A, Ozbel Y, Boelaert M (2008) Spread of vector-borne diseases and neglect of Leishmaniasis, Europe. Emerg Infect Dis 14:1013–1018

    Article  PubMed  Google Scholar 

  14. Ready PD (2010) Leishmaniasis emergence in Europe. Euro Surveill 15:19505

    PubMed  CAS  Google Scholar 

  15. Maroli M, Rossi L, Baldelli R, Capelli G, Ferroglio E, Genchi C, Gramiccia M, Mortarino M, Pietrobelli M, Gradoni L (2008) The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop Med Int Health 13:256–264

    Article  PubMed  Google Scholar 

  16. Morosetti G, Bongiorno G, Beran B, Scalone A, Moser J, Gramiccia M, Gradoni L, Maroli M (2009) Risk assessment for canine leishmaniasis spreading in the north of Italy. Geospat Health 4:115–127

    PubMed  Google Scholar 

  17. Biglino A, Bolla C, Concialdi E, Trisciuoglio A, Romano A, Ferroglio E (2010) Asymptomatic Leishmania infantum infection in an area of Northwestern Italy (Piedmont Region) where such infections are traditionally nonendemic. J Clin Microbiol 48:131–136

    Article  PubMed  Google Scholar 

  18. Naucke TJ, Schmitt C (2004) Is leishmaniasis becoming endemic in Germany? Int J Med Microbiol 293:179–181

    PubMed  Google Scholar 

  19. Naucke TJ, Menn B, Massberg D, Lorentz S (2008) Sandflies and leishmaniasis in Germany. Parasitol Res 103(Suppl 1):S65–S68

    Article  PubMed  Google Scholar 

  20. Postigo JA (2010) Leishmaniasis in the World Health Organization Eastern Mediterranean Region. Int J Antimicrob Agents 36(Suppl 1):S62–S65

    Article  PubMed  CAS  Google Scholar 

  21. Mosleh IM, Geith E, Natsheh L, Abdul-Dayem M, Abotteen N (2008) Cutaneous leishmaniasis in the Jordanian side of the Jordan Valley: severe under-reporting and consequences on public health management. Trop Med Int Health 13:855–860

    Article  PubMed  Google Scholar 

  22. Romero GA, Boelaert M (2010) Control of visceral leishmaniasis in Latin America—a systematic review. PLoS Negl Trop Dis 4:e584

    Article  PubMed  Google Scholar 

  23. Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, López-Vélez R, Molina R, Moreno J (1997) Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10:298–319

    PubMed  CAS  Google Scholar 

  24. Kubar J, Marty P, Lelièvre A, Quaranta JF, Staccini P, Caroli-Bosc C, Le Fichoux Y (1998) Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection: impact of the CD4+ T-lymphocyte counts. AIDS 12:2147–2153

    Article  PubMed  CAS  Google Scholar 

  25. Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B (2003) Leishmaniasis in HIV infection. J Postgrad Med 49:39–49

    Article  PubMed  CAS  Google Scholar 

  26. Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21:334–359

    Article  PubMed  CAS  Google Scholar 

  27. de la Rosa R, Pineda JA, Delgado J, Macías J, Morillas F, Mira JA, Sánchez-Quijano A, Leal M, Lissen E (2002) Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 40:762–767

    Article  Google Scholar 

  28. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN (2008) Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 46:1702–1709

    Article  PubMed  Google Scholar 

  29. Gorski S, Collin SM, Ritmeijer K, Keus K, Gatluak F, Mueller M, Davidson RN (2010) Visceral leishmaniasis relapse in Southern Sudan (1999–2007): a retrospective study of risk factors and trends. PLoS Negl Trop Dis 4:e705

    Article  PubMed  Google Scholar 

  30. Petrela R, Kuneshka L, Foto E, Zavalani F, Gradoni L (2010) Pediatric visceral leishmaniasis in Albania: a retrospective analysis of 1,210 consecutive hospitalized patients (1995–2009). PLoS Negl Trop Dis 4:e814

    Article  Google Scholar 

  31. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M (2008) Leishmaniasis among organ transplant recipients. Lancet Infect Dis 8:191–199

    Article  PubMed  Google Scholar 

  32. Veroux M, Corona D, Giuffrida G, Cacopardo B, Sinagra N, Tallarita T, Giaquinta A, Zerbo D, Veroux PF (2010) Visceral leishmaniasis in the early post-transplant period after kidney transplantation: clinical features and therapeutic management. Transpl Infect Dis 12:387–391

    Article  PubMed  CAS  Google Scholar 

  33. Weisser M, Khanlari B, Terracciano L, Arber C, Gratwohl A, Bassetti S, Hatz C, Battegay M, Flückiger U (2007) Visceral leishmaniasis: a threat to immunocompromised patients in non-endemic areas? Clin Microbiol Infect 13:751–753

    Article  PubMed  CAS  Google Scholar 

  34. Xynos ID, Tektonidou MG, Pikazis D, Sipsas NV (2009) Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. Emerg Infect Dis 15:956–959

    Article  PubMed  Google Scholar 

  35. Cascio A, Iaria M, Iaria C (2010) Leishmaniasis and biologic therapies for rheumatologic diseases. Semin Arthritis Rheum 40:e3–e5

    Article  PubMed  Google Scholar 

  36. De Leonardis F, Govoni M, Lo Monaco A, Trotta F (2009) Visceral leishmaniasis and anti-TNF-α therapy: case report and review of the literature. Clin Exp Rheumatol 27:503–506

    PubMed  Google Scholar 

  37. Mueller MC, Fleischmann E, Grunke M, Schewe S, Bogner JR, Löscher T (2009) Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab. Am J Trop Med Hyg 81:52–54

    PubMed  Google Scholar 

  38. Kopterides P, Mourtzoukou EG, Skopelitis E, Tsavaris N, Falagas ME (2007) Aspects of the association between leishmaniasis and malignant disorders. Trans R Soc Trop Med Hyg 101:1181–1189

    Article  PubMed  Google Scholar 

  39. Antinori S, Gianelli E, Calattini S, Longhi E, Gramiccia M, Corbellino M (2005) Cutaneous leishmaniasis: an increasing threat for travellers. Clin Microbiol Infect 11:343–346

    Article  PubMed  CAS  Google Scholar 

  40. Pavli A, Maltezou HC (2010) Leishmaniasis, an emerging infection in travellers. Int J Infect Dis 14:e1032–e1039

    Article  PubMed  Google Scholar 

  41. Schwartz E, Hatz C, Blum J (2006) New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 6:342–349

    Article  PubMed  Google Scholar 

  42. Weina PJ, Neafie RC, Wortmann G, Polhemus M, Aronson NE (2004) Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis 39:1674–1680

    Article  PubMed  Google Scholar 

  43. van Thiel PP, Leenstra T, de Vries HJ, van der Sluis A, van Gool T, Krull AC, van Vugt M, de Vries PJ, Zeegelaar JE, Bart A, van der Meide WF, Schallig HD, Faber WR, Kager PA (2010) Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment. Am J Trop Med Hyg 83:1295–1300

    Article  PubMed  Google Scholar 

  44. Lederman ER, Weld LH, Elyazar IRF, von Sonnenburg F, Loutan L, Schwartz E, Keystone JS (2008) Dermatologic conditions of the ill returned traveler: an analysis from the GeoSentinel Surveillance Network. Int J Infect Dis 12:593–602

    Article  PubMed  Google Scholar 

  45. Pintado V, Martín-Rabadán P, Rivera ML, Moreno S, Bouza E (2001) Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80:54–73

    Article  CAS  Google Scholar 

  46. López-Vélez R (2003) The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann Trop Med Parasitol 97(Suppl 1):143–147

    Article  PubMed  Google Scholar 

  47. Mary C, Faraut F, Lascombe L, Dumon H (2004) Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol 42:5249–5255

    Article  PubMed  CAS  Google Scholar 

  48. Antinori S, Calattini S, Piolini R, Longhi E, Bestetti G, Cascio A, Parravicini C, Corbellino M (2009) Is real-time polymerase chain reaction (PCR) more useful than a conventional PCR for the clinical management of leishmaniasis? Am J Trop Med Hyg 81:46–51

    PubMed  CAS  Google Scholar 

  49. Bourgeois N, Bastien P, Reynes J, Makinson A, Rouanet I, Lachaud L (2010) ‘Active chronic visceral leishmaniasis’ in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients. HIV Med 11:670–673

    Article  PubMed  CAS  Google Scholar 

  50. Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, Foschi A, Trovati S, Parravicini C, Corbellino M, Meroni L (2007) Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 157:1032–1036

    Article  PubMed  CAS  Google Scholar 

  51. Sinha S, Fernández G, Kapila R, Lambert WC, Schwartz RA (2008) Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome. Int J Dermatol 47:1263–1270

    Article  PubMed  Google Scholar 

  52. Dettwiler S, McKee T, Hadaya K, Chappuis F, van Delden C, Moll S (2010) Visceral leishmaniasis in a kidney transplant recipient: parasitic interstitial nephritis, a cause of renal dysfunction. Am J Transpl 10:1486–1489

    Article  CAS  Google Scholar 

  53. Simon I, Wissing KM, Del Marmol V, Antinori S, Remmelink M, Nilufer Broeders E, Nortier JL, Corbellino M, Abramowicz D, Cascio A (2011) Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature. Transpl Infect Dis. doi:10.1111/j.1399-3062.2011.00598.x

    Google Scholar 

  54. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7:581–596

    Article  PubMed  Google Scholar 

  55. Akilov OE, Khachemoune A, Hasan T (2007) Clinical manifestations and classification of Old World cutaneous leishmaniasis. Int J Dermatol 46:132–142

    Article  PubMed  Google Scholar 

  56. Maniscalco M, Noto G, Zichichi L, Veraldi S (2007) Multifocal cutaneous leishmaniasis: a new clinical presentation of the disease. Acta Derm Venereol 87:275–276

    PubMed  Google Scholar 

  57. Lindoso JA, Barbosa RN, Posada-Vergara MP, Duarte MI, Oyafuso LK, Amato VS, Goto H (2009) Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol 160:311–318

    Article  PubMed  CAS  Google Scholar 

  58. Antinori S, Calattini S, Longhi E, Bestetti G, Piolini R, Magni C, Orlando G, Gramiccia M, Acquaviva V, Foschi A, Corvasce S, Colomba C, Titone L, Parravicini C, Cascio A, Corbellino M (2007) Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature. Clin Infect Dis 44:1602–1610

    Article  PubMed  CAS  Google Scholar 

  59. Bensoussan E, Nasereddin A, Jonas F, Schnur LF, Jaffe CL (2006) Comparison of PCR assays for diagnosis of cutaneous leishmaniasis. J Clin Microbiol 44:1435–1439

    Article  PubMed  CAS  Google Scholar 

  60. Verma S, Kumar R, Katara GK, Singh LC, Negi NS, Ramesh V, Salotra P (2010) Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. PLoS One 5:e10107

    Article  PubMed  Google Scholar 

  61. Romero I, Téllez J, Suárez Y, Cardona M, Figueroa R, Zelazny A, Gore Saravia N (2010) Viability and burden of Leishmania in extralesional sites during human dermal leishmaniasis. PLoS Negl Trop Dis 4:e819

    Article  Google Scholar 

  62. Srivastava P, Dayama A, Mehrotra S, Sundar S (2011) Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg 105:1–6

    Article  PubMed  Google Scholar 

  63. Boelaert M, El-Safi S, Hailu A, Mukhtar M, Rijal S, Sundar S, Wasunna M, Aseffa A, Mbui J, Menten J, Desjeux P, Peeling RW (2008) Diagnostic tests for Kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg 102:32–40

    Article  PubMed  CAS  Google Scholar 

  64. Pattabhi S, Whittle J, Mohamath R, El-Safi S, Moulton GG, Guderian JA, Colombara D, Abdoon AO, Mukhtar MM, Mondal D, Esfandiari J, Kumar S, Chun P, Reed SG, Bhatia A (2010) Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis. PLoS Negl Trop Dis 4:e822

    Article  Google Scholar 

  65. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW (2010) Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362:504–512

    Article  PubMed  CAS  Google Scholar 

  66. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW (2001) Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 323:419–422

    Article  PubMed  CAS  Google Scholar 

  67. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R (2003) Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37:800–804

    Article  PubMed  CAS  Google Scholar 

  68. Syriopoulou V, Daikos GL, Theodoridou M, Pavlopoulou I, Manolaki AG, Sereti E, Karamboula A, Papathanasiou D, Krikos X, Saroglou G (2003) Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 36:560–566

    Article  PubMed  CAS  Google Scholar 

  69. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK (2007) Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 196:591–598

    Article  PubMed  CAS  Google Scholar 

  70. Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN (2006) A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 43:357–364

    Article  PubMed  CAS  Google Scholar 

  71. Sindermann H, Engel KR, Fischer C, Bommer W (2004) Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 39:1520–1523

    Article  PubMed  CAS  Google Scholar 

  72. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H (2004) Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 38:1266–1272

    Article  PubMed  CAS  Google Scholar 

  73. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A (2007) Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 103:33–40

    Article  PubMed  CAS  Google Scholar 

  74. Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, Berman JD (2008) Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 78:210–211

    PubMed  Google Scholar 

  75. Vélez I, López L, Sánchez X, Mestra L, Rojas C, Rodríguez E (2010) Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 83:351–356

    Article  PubMed  Google Scholar 

  76. van Thiel PP, Leenstra T, Kager PA, de Vries HJ, van Vugt M, van der Meide WF, Bart A, Zeegelaar JE, van der Sluis A, Schallig HD, van Gool T, Faber WR, de Vries PJ (2010) Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 50:80–83

    Article  PubMed  Google Scholar 

  77. Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM (2010) Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4:e912

    Article  PubMed  Google Scholar 

  78. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, de Oliveira Penna G, Lima Machado PR, Talhari S (2011) Randomized controlled clinical trial to assess efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 84:255–260

    Article  PubMed  CAS  Google Scholar 

  79. Keynan Y, Larios OE, Wiseman MC, Plourde M, Ouellette M, Rubinstein E (2008) Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol 19:394–396

    PubMed  Google Scholar 

  80. González U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, Alvar J (2010) Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis 51:409–419

    Article  PubMed  Google Scholar 

  81. Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA (2007) Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 77:266–274

    PubMed  CAS  Google Scholar 

  82. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK (2007) Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356:2571–2581

    Article  PubMed  CAS  Google Scholar 

  83. Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J; Leishmaniasis East Africa Platform (LEAP) group (2010) Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis 4:e709

    Article  PubMed  Google Scholar 

  84. Chappuis F, Alirol E, Worku DT, Mueller Y, Ritmeijer K (2011) High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B. Antimicrob Agents Chemother 55:455–456

    Article  PubMed  CAS  Google Scholar 

  85. Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, Hailu A, Edwards T, Omollo R, Mudawi M, Kokwaro G, El-Hassan A, Khalil E (2010) Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis 4:e855

    Article  PubMed  Google Scholar 

  86. Kim DH, Chung HJ, Bleys J, Ghohestani RF (2009) Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 3:e381

    Article  PubMed  Google Scholar 

  87. Olliaro PL (2010) Drug combinations for visceral leishmaniasis. Curr Opin Infect Dis 29:595–602

    Article  Google Scholar 

  88. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10:184–194

    Article  PubMed  Google Scholar 

  89. Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, Boelaert M (2010) Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis 4:e818

    Article  Google Scholar 

  90. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F (2011) Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 377:477–486

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Sciences L. Sacco, Section of Infectious Diseases and Immunopathology, Università degli Studi di Milano, Via GB Grassi, 74, 20157, Milano, Italy

    S. Antinori, L. Schifanella & M. Corbellino

Authors
  1. S. Antinori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Schifanella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Corbellino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Antinori.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antinori, S., Schifanella, L. & Corbellino, M. Leishmaniasis: new insights from an old and neglected disease. Eur J Clin Microbiol Infect Dis 31, 109–118 (2012). https://doi.org/10.1007/s10096-011-1276-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-011-1276-0

Keywords

Search

Navigation